Intestinal bacteria and colorectal cancer: etiology and treatment

References

• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14:1. doi:10.1371/journal.pbio.1002533.
   Web of Science ®Google Scholar
• Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal cancer. Cancer Cell. 2018;33:954–27. doi:10.1016/j.ccell.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Ternes D, Karta J, Tsenkova M, Wilmes P, Haan S, Letellier E. Microbiome in colorectal cancer: how to get from meta-omics to mechanism? Trends Microbiol. 2020;28:401–423. doi:10.1016/j.tim.2020.01.001.
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–812. doi:10.1038/nrc3610.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. Coli Nature. 2020;580:269–273. doi:10.1038/s41586-020-2080-8.
   PubMed Web of Science ®Google Scholar
• Bell HN, Rebernick RJ, Goyert J, Singhal R, Kuljanin M, Kerk SA, Huang W, Das NK, Andren A, Solanki S, et al. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell. 2022;40(185–200.e6):185–200.e6. doi:10.1016/j.ccell.2021.12.001.
   PubMedGoogle Scholar
• Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33:570–580. doi:10.1016/j.ccell.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new Dimensions. Cancer Discov. 2022;12:31–46. doi:10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002;38:867–871. doi:10.1016/S0959-8049(02)00040-0.
   PubMed Web of Science ®Google Scholar
• Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015;521:43–47. doi:10.1038/nature14415.
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7:153–162. doi:10.1038/nrclinonc.2009.237.
   PubMed Web of Science ®Google Scholar
• Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022;162(715–730.e3):715–730.e3. doi:10.1053/j.gastro.2021.10.035.
   PubMedGoogle Scholar
• Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K, Constitutive OM. NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res. 2009;15:2248–2258. doi:10.1158/1078-0432.CCR-08-1383.
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809. doi:10.1038/nrc2734.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds AB, Washington MK, DuBois RN, Beauchamp RD. Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis. 1998;19:543–549. doi:10.1093/carcin/19.4.543.
   PubMed Web of Science ®Google Scholar
• Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: past, present and future perspectives. World J Gastroenterol. 2020;26:1394–1426. doi:10.3748/wjg.v26.i13.1394.
   PubMed Web of Science ®Google Scholar
• McIntyre RE, Buczacki SJA, Arends MJ, Adams DJ. Mouse models of colorectal cancer as preclinical models. Bioessays. 2015;37:909–920. doi:10.1002/bies.201500032.
   PubMed Web of Science ®Google Scholar
• Cao Y, Oh J, Xue M, Huh WJ, Wang J, Gonzalez-Hernandez JA, Rice TA, Martin AL, Song D, Crawford JM, et al. Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites. Science. 2022;378:eabm3233. doi:10.1126/science.abm3233.
   PubMed Web of Science ®Google Scholar
• Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25:968–976. doi:10.1038/s41591-019-0458-7.
   PubMed Web of Science ®Google Scholar
• Bossuet-Greif N, Vignard J, Taieb F, Mirey G, Dubois D, Petit C, Oswald E, Nougayrède J-P. The colibactin genotoxin generates DNA interstrand cross-links in infected cells. MBio. 2018;9(2).
   PubMed Web of Science ®Google Scholar
• J-P N, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313:848–851. doi:10.1126/science.1127059.
   PubMed Web of Science ®Google Scholar
• Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8:207–217. doi:10.1038/nrmicro2298.
   PubMed Web of Science ®Google Scholar
• Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359:592–597. doi:10.1126/science.aah3648.
   PubMed Web of Science ®Google Scholar
• Dubinsky V, Dotan I, Gophna U. Carriage of colibactin-producing bacteria and colorectal cancer risk. Trends Microbiol. 2020;28:874–876. doi:10.1016/j.tim.2020.05.015.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–123. doi:10.1126/science.1224820.
   PubMed Web of Science ®Google Scholar
• Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R, Battista JR. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS ONE. 2013;8:e56964. doi:10.1371/journal.pone.0056964.
   PubMed Web of Science ®Google Scholar
• Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014;20:859–867. doi:10.1158/1078-0432.CCR-13-1343.
   PubMed Web of Science ®Google Scholar
• Yang Y, Gharaibeh RZ, Newsome RC, Jobin C. Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat Cancer. 2020;1:723–734. doi:10.1038/s43018-020-0078-7.
   PubMedGoogle Scholar
• Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, Fodor AA, Jobin C. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014;5:4724. doi:10.1038/ncomms5724.
   PubMed Web of Science ®Google Scholar
• Xue M, Kim CS, Healy AR, Wernke KM, Wang Z, Frischling MC, Shine EE, Wang W, Herzon SB, Crawford JM. Structure elucidation of colibactin and its DNA cross-links. Science. 2019;365(6457).
   Google Scholar
• Dziubańska-Kusibab PJ, Berger H, Battistini F, Bouwman BAM, Iftekhar A, Katainen R, Cajuso T, Crosetto N, Orozco M, Aaltonen LA, et al. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer. Nat Med. 2020;26:1063–1069. doi:10.1038/s41591-020-0908-2.
   PubMed Web of Science ®Google Scholar
• Healy AR, Wernke KM, Kim CS, Lees NR, Crawford JM, Herzon SB. Synthesis and reactivity of precolibactin 886. Nat Chem. 2019;11:890–898. doi:10.1038/s41557-019-0338-2.
   PubMed Web of Science ®Google Scholar
• Wernke KM, Xue M, Tirla A, Kim CS, Crawford JM, Herzon SB. Structure and bioactivity of colibactin. Bioorg Med Chem Lett. 2020;30:127280. doi:10.1016/j.bmcl.2020.127280.
   PubMed Web of Science ®Google Scholar
• Zhou T, Hirayama Y, Tsunematsu Y, Suzuki N, Tanaka S, Uchiyama N, Goda Y, Yoshikawa Y, Iwashita Y, Sato M, et al. Isolation of new colibactin metabolites from wild-type escherichia coli and in situ trapping of a mature colibactin derivative. J Am Chem Soc. 2021;143:5526–5533. doi:10.1021/jacs.1c01495.
   PubMed Web of Science ®Google Scholar
• Reuter C, Alzheimer M, Walles H, Oelschlaeger TA. An adherent mucus layer attenuates the genotoxic effect of colibactin. Cell Microbiol. 2018;35(20).
   PubMed Web of Science ®Google Scholar
• Tomkovich S, Jobin C. Microbial networking in cancer: when two toxins collide. Br J Cancer. 2018;118:1407–1409. doi:10.1038/s41416-018-0101-2.
   PubMed Web of Science ®Google Scholar
• Dougherty MW, Jobin C. Shining a light on colibactin biology. Toxins (Basel). 2021;13. doi:10.3390/toxins14010013.
   PubMed Web of Science ®Google Scholar
• Zhu W, Miyata N, Winter MG, Arenales A, Hughes ER, Spiga L, Kim J, Sifuentes-Dominguez L, Starokadomskyy P, Gopal P, et al. Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer. J Exp Med. 2019;216:2378–2393. doi:10.1084/jem.20181939.
   PubMed Web of Science ®Google Scholar
• Tronnet S, Garcie C, Rehm N, Dobrindt U, Oswald E, Martin P, Bäumler AJ. Iron homeostasis regulates the genotoxicity of escherichia coli that produces colibactin. Infect Immun. 2016;84:3358–3368. doi:10.1128/IAI.00659-16.
   PubMed Web of Science ®Google Scholar
• Tronnet S, Garcie C, Brachmann AO, Piel J, Oswald E, Martin P. High iron supply inhibits the synthesis of the genotoxin colibactin by pathogenic Escherichia coli through a non-canonical Fur/RyhB-mediated pathway. Pathog Dis. 2017;75(5).
   PubMed Web of Science ®Google Scholar
• Wallenstein A, Rehm N, Brinkmann M, Selle M, Bossuet-Greif N, Sauer D, Bunk B, Spröer C, Wami HT, Homburg S, et al. ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli. mSphere. 2020;5(4).
   Web of Science ®Google Scholar
• Chagneau CV, Garcie C, Bossuet-Greif N, Tronnet S, Brachmann AO, Piel J, J-P N, Martin P, Oswald E. The polyamine spermidine modulates the production of the bacterial genotoxin colibactin. mSphere. 2019;4(5).
   PubMed Web of Science ®Google Scholar
• Bossuet-Greif N, Guyonnet C, Chagneau C, Tang-Fichaux M, Penary M, Branchu P, Oswald E, Nougayrede J-P. Oxygen inhibits colibactin production by Escherichia coli. BioRxiv. 2022.
   Google Scholar
• Oliero M, Calvé A, Fragoso G, Cuisiniere T, Hajjar R, Dobrindt U, Santos MM. Oligosaccharides increase the genotoxic effect of colibactin produced by pks+ Escherichia coli strains. BMC Cancer. 2021;21:172. doi:10.1186/s12885-021-07876-8.
   PubMed Web of Science ®Google Scholar
• Arima K, Zhong R, Ugai T, Zhao M, Haruki K, Akimoto N, Lau MC, Okadome K, Mehta RS, Väyrynen JP, et al. Western-style diet, pks island-carrying escherichia coli, and colorectal cancer: analyses from two large prospective cohort studies. Gastroenterology. 2022;163:862–874. doi:10.1053/j.gastro.2022.06.054.
   PubMed Web of Science ®Google Scholar
• Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, Georgakopoulos N, Torrente F, Noorani A, Goddard M, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574:532–537. doi:10.1038/s41586-019-1672-7.
   PubMed Web of Science ®Google Scholar
• Secher T, Brehin C, Oswald E. Early settlers: which E. coli strains do you not want at birth?. Am J Physiol Gastrointest Liver Physiol. 2016;311:G123–9. doi:10.1152/ajpgi.00091.2016.
   PubMed Web of Science ®Google Scholar
• Tsunematsu Y, Hosomi K, Kunisawa J, Sato M, Shibuya N, Saito E, Murakami H, Yoshikawa Y, Iwashita Y, Miyoshi N, et al. Mother-to-infant transmission of the carcinogenic colibactin-producing bacteria. BMC Microbiol. 2021;21:235. doi:10.1186/s12866-021-02292-1.
   PubMed Web of Science ®Google Scholar
• Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, Sauvanet P, Darcha C, Déchelotte P, Bonnet M, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 2014;63:1932–1942. doi:10.1136/gutjnl-2013-305257.
   PubMed Web of Science ®Google Scholar
• Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut Microbes. 2014;5:675–680. doi:10.4161/19490976.2014.969989.
   PubMed Web of Science ®Google Scholar
• Lopès A, Billard E, Casse AH, Villéger R, Veziant J, Roche G, Carrier G, Sauvanet P, Briat A, Pagès F, et al. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. Int J Cancer. 2020;146:3147–3159. doi:10.1002/ijc.32920.
   PubMed Web of Science ®Google Scholar
• Périchon B, Lichtl-Häfele J, Bergsten E, Delage V, Trieu-Cuot P, Sansonetti P, Sobhani I, Dramsi S. Detection of streptococcus gallolyticus and four other crc-associated bacteria in patient stools reveals a potential “driver” role for enterotoxigenic bacteroides fragilis. Front Cell Infect Microbiol. 2022;12:794391. doi:10.3389/fcimb.2022.794391.
   PubMed Web of Science ®Google Scholar
• Prindiville TP, Sheikh RA, Cohen SH, Tang YJ, Cantrell MC, Silva J. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerging Infect Dis. 2000;6:171–174. doi:10.3201/eid0602.000210.
   PubMed Web of Science ®Google Scholar
• Franco AA, Mundy LM, Trucksis M, Wu S, Kaper JB, Sears CL. Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect Immun. 1997;65:1007–1013. doi:10.1128/iai.65.3.1007-1013.1997.
   PubMed Web of Science ®Google Scholar
• Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, DeStefano Shields CE, Dejea CM, Fathi P, Chen J, Finard BB, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 2018;23(203–214.e5). doi:10.1016/j.chom.2018.02.004.
   Google Scholar
• Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM, McDowell A. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS ONE. 2015;10:e0119462. doi:10.1371/journal.pone.0119462.
   PubMed Web of Science ®Google Scholar
• Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC, et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015;60:208–215. doi:10.1093/cid/ciu787.
   PubMed Web of Science ®Google Scholar
• Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016–1022. doi:10.1038/nm.2015.
   PubMed Web of Science ®Google Scholar
• Geis AL, Fan H, Wu X, Wu S, Huso DL, Wolfe JL, Sears CL, Pardoll DM, Regulatory T-cell HF. Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis. Cancer Discov. 2015;5:1098–1109. doi:10.1158/2159-8290.CD-15-0447.
   PubMed Web of Science ®Google Scholar
• Wu S, Morin PJ, Maouyo D, Sears CL. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology. 2003;124:392–400. doi:10.1053/gast.2003.50047.
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015;149(1204–1225.e12):1204–1225.e12. doi:10.1053/j.gastro.2015.07.011.
   PubMedGoogle Scholar
• Liu -Q-Q, Li C-M, Fu L-N, Wang H-L, Tan J, Wang Y-Q, Sun D-F, Gao Q-Y, Chen Y-X, Fang J-Y. Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B. Gut Microbes. 2020;12:1788900. doi:10.1080/19490976.2020.1788900.
   PubMedGoogle Scholar
• Allen J, Hao S, Sears CL, Timp W. Epigenetic Changes Induced by Bacteroides fragilis Toxin. Infect Immun. 2019;87(6).
   Web of Science ®Google Scholar
• DeStefano Shields CE, White JR, Chung L, Wenzel A, Hicks JL, Tam AJ, Chan JL, Dejea CM, Fan H, Michel J, et al. Bacterial-driven inflammation and mutant braf expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy. Cancer Discov. 2021;11:1792–1807. doi:10.1158/2159-8290.CD-20-0770.
   PubMed Web of Science ®Google Scholar
• Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci USA. 2011;108:15354–15359. doi:10.1073/pnas.1010203108.
   PubMed Web of Science ®Google Scholar
• Allen J, Rosendahl Huber A, Pleguezuelos-Manzano C, Puschhof J, Wu S, Wu X, Boot C, Saftien A, O’Hagan HM, Wang H, et al. Colon tumors in enterotoxigenic bacteroides fragilis (ETBF)-colonized mice do not display a unique mutational signature but instead possess host-dependent alterations in the APC Gene. Microbiol Spectr. 2022;10:e0105522. doi:10.1128/spectrum.01055-22.
   PubMed Web of Science ®Google Scholar
• Khodaverdi N, Zeighami H, Jalilvand A, Haghi F, Hesami N. High frequency of enterotoxigenic Bacteroides fragilis and Enterococcus faecalis in the paraffin-embedded tissues of Iranian colorectal cancer patients. BMC Cancer. 2021;21:1353. doi:10.1186/s12885-021-09110-x.
   PubMed Web of Science ®Google Scholar
• Zamani S, Taslimi R, Sarabi A, Jasemi S, Sechi LA, Feizabadi MM. Enterotoxigenic Bacteroides fragilis: a Possible Etiological Candidate for Bacterially-Induced Colorectal Precancerous and Cancerous Lesions. Front Cell Infect Microbiol. 2019;9:449. doi:10.3389/fcimb.2019.00449.
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306. doi:10.1101/gr.126516.111.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–298. doi:10.1101/gr.126573.111.
   PubMed Web of Science ®Google Scholar
• Wang N, Fang J-Y. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 2022;31(2):159–172. doi:10.1016/j.tim.2022.08.010.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–215. doi:10.1016/j.chom.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206. doi:10.1016/j.chom.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Brennan CA, Clay SL, Lavoie SL, Bae S, Lang JK, Fonseca-Pereira D, Rosinski KG, Ou N, Glickman JN, Garrett WS. Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression. Gut Microbes. 2021;13:1987780. doi:10.1080/19490976.2021.1987780.
   PubMed Web of Science ®Google Scholar
• Abed J, JEM E, Zamir G, Faroja M, Almogy G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA, et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host Microbe. 2016;20:215–225. doi:10.1016/j.chom.2016.07.006.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng Y, Yu J, Chen T, Wu Y, Shi L, Li Q, Wu J, Fu X. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget. 2017;8:31802–31814. doi:10.18632/oncotarget.15992.
   PubMedGoogle Scholar
• Rubinstein MR, Baik JE, Lagana SM, Han RP, Raab WJ, Sahoo D, Dalerba P, Wang TC, Han YW. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 2019;20(4).
   PubMed Web of Science ®Google Scholar
• Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015;1:653–661. doi:10.1001/jamaoncol.2015.1377.
   PubMed Web of Science ®Google Scholar
• Guo S, Chen J, Chen F, Zeng Q, Liu W-L ZG. Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16. Gut. 2020. doi:10.1136/gutjnl-2020-321187.
   Web of Science ®Google Scholar
• Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, Chen Z, Wang L, Long Y, Hou T, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13:1980347. doi:10.1080/19490976.2021.1980347.
   PubMed Web of Science ®Google Scholar
• Chen S, Su T, Zhang Y, Lee A, He J, Ge Q, Wang L, Si J, Zhuo W, Wang L. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut Microbes. 2020;11:511–525. doi:10.1080/19490976.2019.1695494.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen Y, Zhang J, Cao P, Su W, Deng Y, Zhan N, Fu X, Huang Y, Dong W. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics. 2020;10:323–339. doi:10.7150/thno.38870.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang L, Li M, Zhang Y, Sun M, Wang L, Lin J, Cui Y, Chen Q, Jin C, et al. Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis. Nat Commun. 2022;13:1248. doi:10.1038/s41467-022-28913-5.
   PubMed Web of Science ®Google Scholar
• Sears CL, Pardoll DM. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis. 2011;203:306–311. doi:10.1093/jinfdis/jiq061.
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10:575–582. doi:10.1038/nrmicro2819.
   PubMed Web of Science ®Google Scholar
• Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, Ding X, Jing X, Jiang C, Jiang N, Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, Ding X, Jing X, Jiang C, Jiang N, et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J Exp Clin Cancer Res. 2020;39:202. 10.1186/s13046-020-01677-w.
   PubMed Web of Science ®Google Scholar
• Yu Y-N, Yu T-C, Zhao H-J, Sun -T-T, Chen H-M, Chen H-Y, An H-F, Weng Y-R, Yu J, Li M, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget. 2015;6:32013–32026. doi:10.18632/oncotarget.5166.
   PubMedGoogle Scholar
• Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, JEM E, Klutstein M, Tayeb S, Almogy G, Atlan KA, et al. Colon cancer-associated fusobacterium nucleatum may originate from the oral cavity and reach colon tumors via the circulatory system. Front Cell Infect Microbiol. 2020;10:400. doi:10.3389/fcimb.2020.00400.
   PubMedGoogle Scholar
• Komiya Y, Shimomura Y, Higurashi T, Sugi Y, Arimoto J, Umezawa S, Uchiyama S, Matsumoto M, Nakajima A. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut. 2019;68:1335–1337. doi:10.1136/gutjnl-2018-316661.
   PubMed Web of Science ®Google Scholar
• Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443–1448. doi:10.1126/science.aal5240.
   PubMed Web of Science ®Google Scholar
• Tomkovich S, Yang Y, Winglee K, Gauthier J, Mühlbauer M, Sun X, Mohamadzadeh M, Liu X, Martin P, Wang GP, et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res. 2017;77:2620–2632. doi:10.1158/0008-5472.CAN-16-3472.
   PubMed Web of Science ®Google Scholar
• Queen J, JC D, JR W, Stevens C, Udayasuryan B, Ttd N, Wu S, Ding H, Fan H, McMann M, et al. Comparative Analysis of Colon Cancer-Derived Fusobacterium nucleatum Subspecies: inflammation and Colon Tumorigenesis in Murine Models. MBio. 2022;13:e0299121. doi:10.1128/mbio.02991-21.
   Web of Science ®Google Scholar
• Kong C, Liang L, Liu G, Du L, Yang Y, Liu J, Shi D, Li X, Ma Y. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut. 2022;gutjnl-2022–327156. doi:10.1136/gutjnl-2022-327156.
   Web of Science ®Google Scholar
• Liu W, Zhang X, Xu H, Li S, Lau -HC-H, Chen Q, Zhang B, Zhao L, Chen H, Sung JJ-Y, et al. Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis. Gastroenterology. 2021;160:2395–2408. doi:10.1053/j.gastro.2021.02.020.
   PubMed Web of Science ®Google Scholar
• Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M, Takahashi H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–1268. doi:10.1002/ijc.29488.
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65:1973–1980. doi:10.1136/gutjnl-2015-310101.
   PubMed Web of Science ®Google Scholar
• Brennan CA, Nakatsu G, Gallini Comeau CA, Drew DA, Glickman JN, Schoen RE, Chan AT, Garrett WS. Aspirin modulation of the colorectal cancer-associated microbe fusobacterium nucleatum. MBio. 2021;12(2).
   PubMed Web of Science ®Google Scholar
• Mughini-Gras L, Schaapveld M, Kramers J, Mooij S, Neefjes-Borst EA. Pelt W van, Neefjes J. Increased colon cancer risk after severe Salmonella infection. PLoS ONE. 2018;13:e0189721. doi:10.1371/journal.pone.0189721.
   PubMed Web of Science ®Google Scholar
• Duijster JW, Hansen JV, Franz E, Neefjes JJC, Frisch M, Mughini-Gras L, Ethelberg S. Association between Salmonella infection and colon cancer: a nationwide registry-based cohort study. Epidemiol Infect. 2021;149:e56. doi:10.1017/S0950268821000285.
   PubMed Web of Science ®Google Scholar
• Kato I, Boleij A, Kortman GAM, Roelofs R, Djuric Z, Severson RK, Tjalsma H. Partial associations of dietary iron, smoking and intestinal bacteria with colorectal cancer risk. Nutr Cancer. 2013;65:169–177. doi:10.1080/01635581.2013.748922.
   PubMed Web of Science ®Google Scholar
• Lu R, Bosland M, Xia Y, Zhang Y-G, Kato I, Sun J. Presence of Salmonella AvrA in colorectal tumor and its precursor lesions in mouse intestine and human specimens. Oncotarget. 2017;8:55104–55115. doi:10.18632/oncotarget.19052.
   PubMedGoogle Scholar
• Lu R, Wu S, Zhang Y-G, Xia Y, Zhou Z, Kato I, Dong H, Bissonnette M, Sun J. Salmonella protein avra activates the STAT3 signaling pathway in colon cancer. Neoplasia. 2016;18:307–316. doi:10.1016/j.neo.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Lu R, Wu S, Zhang YG, Xia Y, Liu X, Zheng Y, Chen H, Schaefer KL, Zhou Z, Bissonnette M, et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis. 2014;3:e105. doi:10.1038/oncsis.2014.20.
   PubMed Web of Science ®Google Scholar
• Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology. 2004;127:80–93. doi:10.1053/j.gastro.2004.03.054.
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Khilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber J, Lochs H. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology. 1998;115:281–286. doi:10.1016/S0016-5085(98)70194-5.
   PubMed Web of Science ®Google Scholar
• Magdy A, Elhadidy M, Abd Ellatif ME, El Nakeeb A, Abdallah E, Thabet W, Youssef M, Khafagy W, Morshed M, Farid M. Enteropathogenic Escherichia coli (EPEC): does it have a role in colorectal tumourigenesis? A Prospective Cohort Study. Int J Surg. 2015;18:169–173. doi:10.1016/j.ijsu.2015.04.077.
   PubMed Web of Science ®Google Scholar
• Roxas JL, Koutsouris A, Viswanathan VK. Enteropathogenic Escherichia coli-induced epidermal growth factor receptor activation contributes to physiological alterations in intestinal epithelial cells. Infect Immun. 2007;75:2316–2324. doi:10.1128/IAI.01690-06.
   PubMed Web of Science ®Google Scholar
• Taieb F, J-P N, Watrin C, Samba-Louaka A, Oswald E. Escherichia coli cyclomodulin Cif induces G2 arrest of the host cell cycle without activation of the DNA-damage checkpoint-signalling pathway. Cell Microbiol. 2006;8:1910–1921. doi:10.1111/j.1462-5822.2006.00757.x.
   PubMed Web of Science ®Google Scholar
• Samba-Louaka A, J-P Nougayrède, Watrin C, Oswald E, Taieb F. The enteropathogenic Escherichia coli effector Cif induces delayed apoptosis in epithelial cells. Infect Immun. 2009;77:5471–5477. doi:10.1128/IAI.00860-09.
   PubMed Web of Science ®Google Scholar
• J-P Nougayrède, Taieb F, De Rycke J, Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trends Microbiol. 2005;13:103–110. doi:10.1016/j.tim.2005.01.002.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Aung KM, Uhlin BE, Wai SN. Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from Escherichia coli. Sci Rep. 2018;8:17780. doi:10.1038/s41598-018-36036-5.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Kim J, Do KH, Park SH, Moon Y. Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination. Oncogene. 2013;32:4960–4969. doi:10.1038/onc.2012.508.
   PubMed Web of Science ®Google Scholar
• Fabbri A, Travaglione S, Rosadi F, Ballan G, Maroccia Z, Giambenedetti M, Guidotti M, Ødum N, Krejsgaard T, Fiorentini C. The Escherichia coli protein toxin cytotoxic necrotizing factor 1 induces epithelial mesenchymal transition. Cell Microbiol. 2020;22:e13138. doi:10.1111/cmi.13138.
   PubMed Web of Science ®Google Scholar
• Drewes JL, Chen J, Markham NO, Knippel RJ, Domingue JC, Tam AJ, Chan JL, Kim L, McMann M, Stevens C, et al. Human colon cancer-derived clostridioides difficile strains drive colonic tumorigenesis in mice. Cancer Discov. 2022;12:1873–1885. doi:10.1158/2159-8290.CD-21-1273.
   PubMed Web of Science ®Google Scholar
• Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, Brisse S, Holt KE. Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in Klebsiella pneumoniae populations. Microb Genom. 2018;4(9).
   PubMed Web of Science ®Google Scholar
• Strakova N, Korena K, Karpiskova R. Klebsiella pneumoniae producing bacterial toxin colibactin as a risk of colorectal cancer development - A systematic review. Toxicon. 2021;197:126–135. doi:10.1016/j.toxicon.2021.04.007.
   PubMed Web of Science ®Google Scholar
• Pope JL, Yang Y, Newsome RC, Sun W, Sun X, Ukhanova M, Neu J, Issa J-P, Mai V, Jobin C. Microbial Colonization Coordinates the Pathogenesis of a Klebsiella pneumoniae Infant Isolate. Sci Rep. 2019;9:3380. doi:10.1038/s41598-019-39887-8.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fu K, Wier EM, Lei Y, Hodgson A, Xu D, Xia X, Zheng D, Ding H, Sears CL, Liu Y, Fu K, Wier EM, Lei Y, Hodgson A, Xu D, Xia X, Zheng D, Ding H, Sears CL, et al. Bacterial genotoxin accelerates transient infection-driven murine colon tumorigenesis. Cancer Discov. 2022;12:236–249. 10.1158/2159-8290.CD-21-0912.
   PubMed Web of Science ®Google Scholar
• Meier B, Volkova NV, Hong Y, Schofield P, Campbell PJ, Gerstung M, Gartner A. Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers. Genome Res. 2018;28:666–675. doi:10.1101/gr.226845.117.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, A-L B-D, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi:10.1038/nature12477.
   PubMed Web of Science ®Google Scholar
• He Z, Gharaibeh RZ, Newsome RC, Pope JL, Dougherty MW, Tomkovich S, Pons B, Mirey G, Vignard J, Hendrixson DR, et al. Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut. 2019;68:289–300. doi:10.1136/gutjnl-2018-317200.
   PubMed Web of Science ®Google Scholar
• Elwell CA, Dreyfus LA. DNase I homologous residues in CdtB are critical for cytolethal distending toxin-mediated cell cycle arrest. Mol Microbiol. 2000;37:952–963. doi:10.1046/j.1365-2958.2000.02070.x.
   PubMed Web of Science ®Google Scholar
• Crawford GE, Davis S, Scacheri PC, Renaud G, Halawi MJ, Erdos MR, Green R, Meltzer PS, Wolfsberg TG, Collins FS. DNase-chip: a high-resolution method to identify DNase I hypersensitive sites using tiled microarrays. Nat Methods. 2006;3:503–509. doi:10.1038/nmeth888.
   PubMed Web of Science ®Google Scholar
• Koohy H, Down TA, Hubbard TJ, Mariño-Ramírez L. Chromatin accessibility data sets show bias due to sequence specificity of the DNase I enzyme. PLoS ONE. 2013;8:e69853. doi:10.1371/journal.pone.0069853.
   PubMed Web of Science ®Google Scholar
• Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23:1298–1303. doi:10.1111/j.1440-1746.2008.05490.x.
   PubMed Web of Science ®Google Scholar
• de Almeida CV, Taddei A, Amedei A. The controversial role of Enterococcus faecalis in colorectal cancer. Therap Adv Gastroenterol. 2018;11:1756284818783606. doi:10.1177/1756284818783606.
   Web of Science ®Google Scholar
• De Almeida CV, Lulli M, Di Pilato V, Schiavone N, Russo E, Nannini G, Baldi S, Borrelli R, Bartolucci G, Menicatti M, et al. Differential responses of colorectal cancer cell lines to enterococcus faecalis’ strains isolated from healthy donors and colorectal cancer patients. J Clin Med. 2019;9:8. doi:10.3390/jcm9010008.
   PubMedGoogle Scholar
• Wang X, Huycke MM. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology. 2007;132:551–561. doi:10.1053/j.gastro.2006.11.040.
   PubMed Web of Science ®Google Scholar
• Wang X, Allen TD, May RJ, Lightfoot S, Houchen CW, Huycke MM. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res. 2008;68:9909–9917. doi:10.1158/0008-5472.CAN-08-1551.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang X, Huycke T, Moore DR, Lightfoot SA, Huycke MM. Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect. Transl Oncol. 2013;6:596–606. doi:10.1593/tlo.13412.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang Y, Huycke MM. Commensal bacteria drive endogenous transformation and tumour stem cell marker expression through a bystander effect. Gut. 2015;64:459–468. doi:10.1136/gutjnl-2014-307213.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang Y, Huycke MM. Commensal-infected macrophages induce dedifferentiation and reprogramming of epithelial cells during colorectal carcinogenesis. Oncotarget. 2017;8:102176–102190. doi:10.18632/oncotarget.22250.
   PubMedGoogle Scholar
• Yang Y, Huycke MM, Herman TS, Glutathione WX. S-transferase alpha 4 induction by activator protein 1 in colorectal cancer. Oncogene. 2016;35:5795–5806. doi:10.1038/onc.2016.113.
   PubMed Web of Science ®Google Scholar
• Lennard KS, Goosen RW, Blackburn JM, Goel A. Bacterially-associated transcriptional remodelling in a distinct genomic subtype of colorectal cancer provides a plausible molecular basis for disease development. PLoS ONE. 2016;11:e0166282. doi:10.1371/journal.pone.0166282.
   PubMed Web of Science ®Google Scholar
• Gaines S, van Praagh JB, Williamson AJ, Jacobson RA, Hyoju S, Zaborin A, Mao J, Koo HY, Alpert L, Bissonnette M, et al. Western diet promotes intestinal colonization by collagenolytic microbes and promotes tumor formation after colorectal surgery. Gastroenterology. 2020;158(958–970.e2):958–970.e2. doi:10.1053/j.gastro.2019.10.020.
   PubMedGoogle Scholar
• Williamson AJ, Jacobson R, van Praagh JB, Gaines S, Koo HY, Lee B, Chan W-C, Weichselbaum R, Alverdy JC, Zaborina O, et al. Enterococcus faecalis promotes a migratory and invasive phenotype in colon cancer cells. Neoplasia. 2022;27:100787. doi:10.1016/j.neo.2022.100787.
   PubMed Web of Science ®Google Scholar
• Iida N, Mizukoshi E, Yamashita T, Yutani M, Seishima J, Wang Z, Arai K, Okada H, Yamashita T, Sakai Y, et al. Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nat Cancer. 2021;2:1039–1054. doi:10.1038/s43018-021-00251-3.
   PubMedGoogle Scholar
• Miyamoto S, Komiya M, Fujii G, Hamoya T, Nakanishi R, Fujimoto K, Tamura S, Kurokawa Y, Takahashi M, Ijichi T, et al. Preventive Effects of Heat-Killed Enterococcus faecalis Strain EC-12 on Mouse Intestinal Tumor Development. Int J Mol Sci. 2017;19:18. doi:10.3390/ijms19010018.
   PubMedGoogle Scholar
• Tsoi H, Chu ESH, Zhang X, Sheng J, Nakatsu G, Ng SC, Chan AWH, Chan FKL, Sung JJY, Yu J. Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology. 2017;152(1419–1433.e5):1419–1433.e5. doi:10.1053/j.gastro.2017.01.009.
   PubMedGoogle Scholar
• Osman MA, Neoh H-M, N-S AM, Chin S-F, Mazlan L, Raja Ali RA, Zakaria AD, Ngiu CS, Ang MY, Jamal R. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci Rep. 2021;11:2925. doi:10.1038/s41598-021-82465-0.
   PubMed Web of Science ®Google Scholar
• Purcell RV, Visnovska M, Biggs PJ, Schmeier S, Frizelle FA. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep. 2017;7:11590. doi:10.1038/s41598-017-11237-6.
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WKK, Ng SC, Tsoi H, Dong Y, Zhang N, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6:8727. doi:10.1038/ncomms9727.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang X, Zhou Y, Fu K, Lau -HC-H, Chun TW-Y, Cheung AH-K, Coker OO, Wei H, Wu W-K-K, et al. Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients. Oncogene. 2022;41:4200–4210. doi:10.1038/s41388-022-02395-7.
   PubMed Web of Science ®Google Scholar
• Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, Coker OO, Chan AWH, Chan FKL, Sung JJY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. 2019;4:2319–2330. doi:10.1038/s41564-019-0541-3.
   PubMed Web of Science ®Google Scholar
• Vega P, Valentín F, Cubiella J. Colorectal cancer diagnosis: pitfalls and opportunities. World J Gastrointest Oncol. 2015;7:422–433. doi:10.4251/wjgo.v7.i12.422.
   PubMed Web of Science ®Google Scholar
• Yuan B, Ma B, Yu J, Meng Q, Du T, Li H, Zhu Y, Sun Z, Ma S, Song C. Fecal Bacteria as Non-Invasive Biomarkers for Colorectal Adenocarcinoma. Front Oncol. 2021;11:664321. doi:10.3389/fonc.2021.664321.
   PubMed Web of Science ®Google Scholar
• Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10:766. doi:10.15252/msb.20145645.
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–78. doi:10.1136/gutjnl-2015-309800.
   PubMed Web of Science ®Google Scholar
• Avuthu N, Guda C, Claesen J. Meta-analysis of altered gut microbiota reveals microbial and metabolic biomarkers for colorectal cancer. Microbiol Spectr. 2022;10:e0001322. doi:10.1128/spectrum.00013-22.
   PubMed Web of Science ®Google Scholar
• Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567–574. doi:10.1038/s41586-020-2095-1.
   PubMed Web of Science ®Google Scholar
• Bosch S, Acharjee A, Quraishi MN, Bijnsdorp IV, Rojas P, Bakkali A, Jansen EE, Stokkers P, Kuijvenhoven J, Pham TV, et al. Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer. Gut Microbes. 2022;14:2139979. doi:10.1080/19490976.2022.2139979.
   PubMed Web of Science ®Google Scholar
• Pessione E. Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Front Cell Infect Microbiol. 2012;2:86. doi:10.3389/fcimb.2012.00086.
   PubMed Web of Science ®Google Scholar
• Kvakova M, Kamlarova A, Stofilova J, Benetinova V, Bertkova I. Probiotics and postbiotics in colorectal cancer: prevention and complementary therapy. World J Gastroenterol. 2022;28:3370–3382. doi:10.3748/wjg.v28.i27.3370.
   PubMed Web of Science ®Google Scholar
• Agah S, Alizadeh AM, Mosavi M, Ranji P, Khavari-Daneshvar H, Ghasemian F, Bahmani S, Tavassoli A. More Protection of Lactobacillus acidophilus Than Bifidobacterium bifidum Probiotics on Azoxymethane-Induced Mouse Colon Cancer. Probiotics Antimicrob Proteins. 2019;11:857–864. doi:10.1007/s12602-018-9425-8.
   PubMed Web of Science ®Google Scholar
• Zhuo Q, Yu B, Zhou J, Zhang J, Zhang R, Xie J, Wang Q, Zhao S. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci Rep. 2019;9:20128.
   PubMed Web of Science ®Google Scholar
• Khalil MA, Sonbol FI, Al-Madboly LA, Aboshady TA, Alqurashi AS, Ali SS. Exploring the therapeutic potentials of exopolysaccharides derived from lactic acid bacteria and bifidobacteria: antioxidant, antitumor, and periodontal regeneration. Front Microbiol. 2022;13:803688. doi:10.3389/fmicb.2022.803688.
   PubMed Web of Science ®Google Scholar
• Konishi H, Fujiya M, Tanaka H, Ueno N, Moriichi K, Sasajima J, Ikuta K, Akutsu H, Tanabe H, Kohgo Y. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016;7:12365. doi:10.1038/ncomms12365.
   PubMed Web of Science ®Google Scholar
• Bi Z, Cui E, Yao Y, Chang X, Wang X, Zhang Y, Xu G-X, Zhuang H, Hua Z-C. Recombinant Bifidobacterium longum carrying endostatin protein alleviates dextran sodium sulfate-induced colitis and colon cancer in rats. Front Microbiol. 2022;13:927277. doi:10.3389/fmicb.2022.927277.
   PubMed Web of Science ®Google Scholar
• Li Q, Hu W, Liu W-X, Zhao L-Y, Huang D, Liu X-D, Chan H, Zhang Y, Zeng J-D, Coker OO, et al. Streptococcus thermophilus Inhibits Colorectal Tumorigenesis Through Secreting β-Galactosidase. Gastroenterology. 2021;160(1179–1193.e14):1179-1193.
   Google Scholar
• Sugimura N, Li Q, Chu ESH, Lau HCH, Fong W, Liu W, Liang C, Nakatsu G, Su ACY, Coker OO, et al. Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut. 2021;71:2011–2021. doi:10.1136/gutjnl-2020-323951.
   PubMed Web of Science ®Google Scholar
• Oh NS, Lee JY, Oh S, Joung JY, Kim SG, Shin YK, Lee K-W, Kim SH, Kim Y. Improved functionality of fermented milk is mediated by the synbiotic interaction between Cudrania tricuspidata leaf extract and Lactobacillus gasseri strains. Appl Microbiol Biotechnol. 2016;100:5919–5932. doi:10.1007/s00253-016-7414-y.
   PubMed Web of Science ®Google Scholar
• Oh NS, Lee JY, Kim Y. The growth kinetics and metabolic and antioxidant activities of the functional synbiotic combination of Lactobacillus gasseri 505 and Cudrania tricuspidata leaf extract. Appl Microbiol Biotechnol. 2016;100:10095–10106. doi:10.1007/s00253-016-7863-3.
   PubMed Web of Science ®Google Scholar
• NS O, JY L, Y-T K, SH K, Lee J-H. Cancer-protective effect of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania tricuspidata leaf extract on colitis-associated colorectal cancer. Gut Microbes. 2020;12:1785803. doi:10.1080/19490976.2020.1785803.
   PubMed Web of Science ®Google Scholar
• Oliver A, Chase AB, Weihe C, Orchanian SB, Riedel SF, Hendrickson CL, Lay M, Sewall JM, Martiny JBH, High-Fiber WK. Whole-Food Dietary Intervention Alters the Human Gut Microbiome but Not Fecal Short-Chain Fatty Acids. mSystems. 2021;6(2).
   Web of Science ®Google Scholar
• Lancaster SM, Lee-McMullen B, Abbott CW, Quijada JV, Hornburg D, Park H, Perelman D, Peterson DJ, Tang M, Robinson A, et al. Global, distinctive, and personal changes in molecular and microbial profiles by specific fibers in humans. Cell Host Microbe. 2022;30(848–862.e7):848–862.e7. doi:10.1016/j.chom.2022.03.036.
   PubMedGoogle Scholar
• Stintzing S. Management of colorectal cancer. F1000Prime Rep. 2014;6:108. doi:10.12703/P6-108.
   PubMedGoogle Scholar
• Nagata N, Nishijima S, Miyoshi-Akiyama T, Kojima Y, Kimura M, Aoki R, Ohsugi M, Ueki K, Miki K, Iwata E, et al. Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology. 2022;163:1038–1052. doi:10.1053/j.gastro.2022.06.070.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–970. doi:10.1126/science.1240527.
   PubMed Web of Science ®Google Scholar
• Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, Comas R, Jimenez J, Elez E, Bullman S, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020;31:1366–1375. doi:10.1016/j.annonc.2020.06.003.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548–563.e16. doi:10.1016/j.cell.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, Cai S. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019;38:14. doi:10.1186/s13046-018-0985-y.
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357:1156–1160. doi:10.1126/science.aah5043.
   PubMed Web of Science ®Google Scholar
• Newsome RC, Gharaibeh RZ, Pierce CM, da Silva WV, Paul S, Hogue SR, Yu Q, Antonia S, Conejo-Garcia JR, Robinson LA, et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 2022;14:35. doi:10.1186/s13073-022-01037-7.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. doi:10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–108. doi:10.1126/science.aao3290.
   PubMed Web of Science ®Google Scholar
• Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–609. doi:10.1126/science.abb5920.
   PubMed Web of Science ®Google Scholar
• Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin J-M, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin J-M, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595–602. 10.1126/science.abf3363.
   PubMed Web of Science ®Google Scholar
• Jobin C. Precision medicine using microbiota. Science. 2018;359:32–34. doi:10.1126/science.aar2946.
   PubMed Web of Science ®Google Scholar
• Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med. 2022;28:535–544. doi:10.1038/s41591-022-01695-5.
   PubMed Web of Science ®Google Scholar
• Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28:315–324. doi:10.1038/s41591-021-01655-5.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369:1481–1489. doi:10.1126/science.abc3421.
   PubMed Web of Science ®Google Scholar
• Griffin ME, Espinosa J, Becker JL, Luo J-D, Carroll TS, Jha JK, Fanger GR, Hang HC. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science. 2021;373:1040–1046. doi:10.1126/science.abc9113.
   PubMed Web of Science ®Google Scholar
• Kawanabe-Matsuda H, Takeda K, Nakamura M, Makino S, Karasaki T, Kakimi K, Nishimukai M, Ohno T, Omi J, Kano K, et al. Dietary lactobacillus-derived exopolysaccharide enhances immune-checkpoint blockade therapy. Cancer Discov. 2022;12:1336–1355. doi:10.1158/2159-8290.CD-21-0929.
   PubMed Web of Science ®Google Scholar
• Iftekhar A, Berger H, Bouznad N, Heuberger J, Boccellato F, Dobrindt U, Hermeking H, Sigal M, Meyer TF. Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells. Nat Commun. 2021;12:1003.
   PubMed Web of Science ®Google Scholar
• Galeano Niño JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, Futran N, Houlton J, Sather C, Sicinska E, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611:810–817. doi:10.1038/s41586-022-05435-0.
   PubMed Web of Science ®Google Scholar
• Schmidt F, Zimmermann J, Tanna T, Farouni R, Conway T, Macpherson AJ, Platt RJ. Noninvasive assessment of gut function using transcriptional recording sentinel cells. Science. 2022;376:eabm6038. doi:10.1126/science.abm6038.
   PubMed Web of Science ®Google Scholar
• Smith AB, Jenior ML, Keenan O, Hart JL, Specker J, Abbas A, Rangel PC, Di C, Green J, Bustin KA, et al. Enterococci enhance Clostridioides difficile pathogenesis. Nature. 2022;611:780–786. doi:10.1038/s41586-022-05438-x.
   PubMed Web of Science ®Google Scholar
• Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021;592:138–143. doi:10.1038/s41586-021-03368-8.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shi T, Lu X, Xu Z, Qu J, Zhang Z, Shi G, Shen S, Hou Y, Chen Y, et al. Fungal-induced glycolysis in macrophages promotes colon cancer by enhancing innate lymphoid cell secretion of IL-22. EMBO J. 2021;40:e105320. doi:10.15252/embj.2020105320.
   PubMed Web of Science ®Google Scholar
• Stern J, Miller G, Li X, Saxena D. Virome and bacteriome: two sides of the same coin. Curr Opin Virol. 2019;37:37–43. doi:10.1016/j.coviro.2019.05.007.
   PubMed Web of Science ®Google Scholar
• Lin Y, Lau HCH, Liu Y, Kang X, Wang Y, Ting NLN, Kwong TNY, Han J, Liu W, Liu C, Lin Y, Lau HC-H, Liu Y, Kang X, Wang Y, Ting NL-N, Kwong TN-Y, Han J, Liu W, Liu C, et al. Altered mycobiota signatures and enriched pathogenic aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology. 2022;163:908–921. 10.1053/j.gastro.2022.06.038.
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, Li X, Szeto C-H, Sugimura N, Lam -TY-T, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology. 2018;155(529–541.e5):529–541.e5. doi:10.1053/j.gastro.2018.04.018.
   PubMedGoogle Scholar
• Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, Chan FKL, Sung JJY, Yu J. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;68:654–662. doi:10.1136/gutjnl-2018-317178.
   PubMed Web of Science ®Google Scholar
• Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe. 2019;25(285–299.e8):285–299.e8. doi:10.1016/j.chom.2019.01.008.
   PubMedGoogle Scholar
• Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, Silberberg Y, Atarashi K, Furuichi M, Oka A, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022;185(2879–2898.e24):2879–2898.e24. doi:10.1016/j.cell.2022.07.003.
   PubMedGoogle Scholar
• Volpe MR, Velilla JA, Daniel-Ivad M, Yao JJ, Stornetta A, Villalta PW, Huang H-C, Bachovchin DA, Balbo S, Gaudet R, et al. A small molecule inhibitor prevents gut bacterial genotoxin production. Nat Chem Biol. 2023;19:159–167. doi:10.1038/s41589-022-01147-8.
   PubMed Web of Science ®Google Scholar
• Velilla JA, Volpe MR, Kenney GE, Walsh RM, Balskus EP, Gaudet R. Structural basis of colibactin activation by the ClbP peptidase. Nat Chem Biol. 2022;19(2):151-158.
   Web of Science ®Google Scholar
• Yue Y, Xu J, Li Y, Cheng K, Feng Q, Ma X, Ma N, Zhang T, Wang X, Zhao X, et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat Biomed Eng. 2022;6:898–909. doi:10.1038/s41551-022-00886-2.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu H, Ye Q, Tao F, Wheeldon I, Yuan A, Hu Y, Wu J. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nat Biomed Eng. 2022;6:44–53. doi:10.1038/s41551-021-00834-6.
   PubMed Web of Science ®Google Scholar
• Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, Mani S, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831–835. doi:10.1126/science.1191175.
   PubMed Web of Science ®Google Scholar